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Several studies support the hypothesis that patients’
prognosis and survival may be modulated not only by
somatic alterations, but also by constitutive genetic fac-
tors. Among the few germline variations that have been
associated with survival and/or clinical prognostic para-
meters of cancer patients is the Gly388Arg polymorph-
ism (rs351855) of the fibroblast growth factor receptor 4
( F G F R 4 )t h a ts h o w e dc o n t r a s t i n gr e s u l t si nd i f f e r e n t
association studies. Here, we assessed the association
between the FGFR4 Gly388Arg polymorphism and can-
cer prognosis carrying out a meta- and pooled analyses
of 6,028 and 2,537 cancer cases, respectively, by nodal
status, clinical stage, and overall survival. A statistically
significant association between FGFR4 Arg388Arg
homozygosity and nodal status was found in the meta-
analysis but not in the pooled analysis adjusted for
confounding factors. In the pooled analysis, Gly388Arg
heterozygous carriers showed an increased hazard of
poor overall survival as compared to homozygous car-
riers of the common Gly388 allele, even after adjusting
for clinical stage or nodal status (HR = 1.24, 95% CI
1.06 – 1.45). These results provide evidence of a role for
the FGFR4 Gly388Arg polymorphism in modulating
patients’ outcome in different types of cancer. The tight
linkage disequilibrium of the polymorphism with mis-
sense and intronic single nucleotide polymorphisms of
the FGFR4 locus might explain the contradictory asso-
ciations of this polymorphism with patient outcome
reported thus far.
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